TIL · Instil Bio, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on TIL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About TIL · Instil Bio, Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Live Quote
SELL (score -8) · 12-1 mom -71.5% · RSI 29.9 · below_both · -76.6% from high
Targets blend Wall Street consensus (1 analysts: low $7.00 / mean $7.00 / high $7.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Instil Bio (TIL) is a pre-revenue biotech shell with no active product pipeline after discontinuing its sole candidate AXN-2510 in January 2026. The stock has collapsed ~78% over the trailing year from $36 to ~$7.95. The investigation trigger was four Form 4 filings within 14 days; however, all four are identical new-hire/board-compensation option grants (transaction code A = award, not open-market P/S purchase). There is no actual insider buying — this is a phantom cluster of routine equity compensation that coincidentally clustered at the same time as the annual board meeting on June 11. No product pipeline, no revenue, $85M debt due January 2027 against ~$74M cash, and options markets are completely illiquid with zero expiries available. This fits 'no_anomaly' — nothing actionable in any direction.
Lessons Referencing This Ticker
RSI(14) > 80 is a valid overbought signal that should reduce the technical_was_useful score and trigger a mean-reversion warning. In the scoring methodology, technical signals should not be dismissed as 'Tier 3 confirmation' when they indicate extreme conditions.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call